Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Thailand and GHIT Fund join forces to tackle infectious diseases

The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand

The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave

As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact

AstraZeneca, Roche-backed study supports risk-based HF screening in diabetes

Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care

Jan Vishwas Bill 2026 decriminalises minor health sector offences, eases compliance burden

Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy

Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety